Comparing the performance of six human papillomavirus tests in a screening population

被引：169

作者：

Cuzick, J. ^{[1
]}

Cadman, L. ^{[1
]}

Mesher, D. ^{[1
]}

Austin, J. ^{[1
]}

Ashdown-Barr, L. ^{[1
]}

Ho, L. ^{[1
]}

Terry, G. ^{[1
]}

Liddle, S. ^{[2
]}

Wright, C. ^{[3
]}

Lyons, D. ^{[4
]}

Szarewski, A. ^{[1
]}

机构：

[1] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London EC1M 6BQ, England

[2] Doctors Lab, London W1T 4EU, England

[3] St Marys Hosp, Dept Cytopathol, London W2 1PG, England

[4] St Marys Hosp, Dept Gynaecol, London W2 1PG, England

来源：

BRITISH JOURNAL OF CANCER | 2013年 / 108卷 / 04期

关键词：

biomarkers; cervix; HPV; CERVICAL INTRAEPITHELIAL NEOPLASIA; HYBRID CAPTURE 2; TERM-FOLLOW-UP; HPV TEST; MESSENGER-RNA; WOMEN; CYTOLOGY; PREDICTORS;

D O I：

10.1038/bjc.2013.22

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Several new assays have been developed for high-risk HPV testing of cervical samples; we compare six HPV tests in a screening population. Methods: Residual material from liquid-based PreservCyt samples was assayed. Four tests (Hybrid Capture 2, Cobas, Abbott and Becton-Dickinson (BD)) measured HPV DNA while two used RNA (APTIMA and NorChip). Results: Positivity rates ranged from 13.4 to 16.3% for the DNA-based tests with a significantly lower positivity rate for the Abbott assay. The Gen-Probe APTIMA assay was positive in 10.3% of women, which was significantly lower than all the DNA tests; the NorChip PreTect HPV-Proofer test was much lower at 5.2%. 40 CIN2 + cases were identified, of which 19 were CIN3 + All CIN3 + cases were HPV positive by all tests except for one, which was negative by the Abbott assay and five which were negative by the NorChip test. Conclusion: All HPV tests except NorChip showed high sensitivity for high-grade lesions positive by cytology, suggesting co-testing is unnecessary when using HPV tests. Positivity rates in cytology-negative specimens were similar for the DNA-based tests, but lower for the APTIMA test suggesting this maintains the high sensitivity of DNA tests, but with better specificity.

引用

页码：908 / 913

页数：6

共 24 条

[11]

Jon S, 2010, IPV MONTR

[12]

LeBar W, 2009, 25 CLIN VIR S DAYT B

[13] Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older [J].